Enanta/$ENTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Enanta
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
- Ticker
- $ENTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 120
- Headquarters
- Watertown, United States
- Website
- www.enanta.com
Enanta Metrics
BasicAdvanced
$355M
-
-$2.34
0.93
-
Price and volume
Market cap
$355M
Beta
0.93
52-week high
$17.15
52-week low
$7.05
Average daily volume
244K
Financial strength
Current ratio
3.759
Quick ratio
3.619
Long term debt to equity
1.399
Total debt to equity
1.801
Interest coverage (TTM)
-4.55%
Profitability
EBITDA (TTM)
-53.819
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-96.89%
Operating margin (TTM)
-89.99%
Effective tax rate (TTM)
-0.16%
Revenue per employee (TTM)
$540,000
Management effectiveness
Return on assets (TTM)
-12.28%
Return on equity (TTM)
-70.12%
Valuation
Price to revenue (TTM)
5.059
Price to book
3.52
Price to tangible book (TTM)
3.51
Price to free cash flow (TTM)
-8.938
Free cash flow yield (TTM)
-11.19%
Free cash flow per share (TTM)
-1.365
Growth
Revenue change (TTM)
0.70%
Earnings per share change (TTM)
-45.94%
3-year revenue growth (CAGR)
-6.79%
10-year revenue growth (CAGR)
-3.15%
3-year earnings per share growth (CAGR)
-28.23%
10-year earnings per share growth (CAGR)
4.45%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Analyst projections of the future price of Enanta stock.
Bulls say / Bears say
FDA feedback allows zelicapavir to move into one registrational Phase 2b/3 study rather than two separate Phase 3 trials. Enanta says its earlier high-risk RSV study showed faster symptom resolution and fewer hospitalisations, giving the lead asset a credible path towards a first approved RSV antiviral. (Enanta Pharmaceuticals)
The RSV opportunity covers both high-risk adults and young children, with the RESOLVE and LOTUS studies expected to produce topline data in 2027. If zelicapavir works in both groups, Enanta could address a sizeable unmet need where no approved antiviral treatment is currently available. (Enanta Pharmaceuticals, Enanta Pharmaceuticals)
Enanta is building a second value engine in immunology, with Phase 1 data due for the KIT inhibitor EDP-978 and planned progress for its STAT6 and MRGPRX2 programmes. Its $211.5 million of cash and marketable securities, plus retained royalties, is expected to fund operations into fiscal 2029, giving it time to reach several catalysts. (Enanta Pharmaceuticals, StockAnalysis)
Enanta remains heavily dependent on AbbVie’s hepatitis C franchise: all third-quarter revenue came from MAVYRET/MAVIRET royalties, which fell to $14.4 million from $18.3 million a year earlier. Further HCV sales erosion would weaken the funding base before the pipeline generates product revenue. (Enanta Pharmaceuticals)
The royalty stream does not convert fully into cash for Enanta because 54.5% of ongoing MAVYRET/MAVIRET royalties is paid to OMERS through 2032. The associated liability carried an estimated 12.8% effective annual imputed interest rate at the latest quarter, and the company has also opened a $75 million at-the-market equity facility, creating potential dilution. (Enanta Pharmaceuticals)
The main value driver is still an unapproved drug whose Phase 2b portion must confirm the earlier RSV result before the Phase 3 stage, with key data not expected until 2027. The immunology assets are earlier still, so a failed trial, safety issue or delay could leave Enanta with continuing losses and no replacement revenue stream. (Enanta Pharmaceuticals, Enanta Pharmaceuticals)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Enanta News
AllArticlesVideos
Funds containing Enanta
AllUSDGBPEUR
Fund name | Fund size | $ENTA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.